Conditions: Pneumonia
Allocation: NON_RANDOMIZED | Intervention model: CROSSOVER
Enrollment: 29
Healthy volunteers: yes

Brief summary:
This study will evaluate what effect renal dysfunction has on a drug that has an intravenous (CP-70,429) and an oral form (PF-03709270).

Detailed description:
To evaluate the pharmacokinetics and safety.

Arms:
arm 1: None

Interventions: intervention 1: CP-70,429 and PF-03709270
Intervention descriptions: intervention 1: Study Periods 1 and 2 will be separated by a minimum of 14 days. In Period 1, subjects will receive a single dose of CP-70429 (800 mg given as a 1.5 hour intravenous infusion), while in Period 2, subjects will receive a single oral dose of PF-03709270 (1000 mg).

Protocol document: